XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

XOMA (NASDAQ:XOMA - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a report released on Thursday.

Separately, HC Wainwright reaffirmed a "buy" rating and set a $123.00 target price on shares of XOMA in a report on Tuesday, January 7th.

XOMA Stock Performance

Shares of XOMA stock traded down $0.83 on Thursday, hitting $27.29. The company's stock had a trading volume of 21,691 shares, compared to its average volume of 38,899. XOMA has a fifty-two week low of $18.57 and a fifty-two week high of $35.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The stock's 50 day moving average is $28.66 and its 200-day moving average is $28.01. The company has a market capitalization of $321.48 million, a PE ratio of -7.84 and a beta of 0.92.

Insider Buying and Selling

In other news, CEO Owen Hughes sold 21,881 shares of the company's stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company's stock, valued at approximately $1,047,621.05. This represents a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets increased its stake in shares of XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company's stock valued at $43,000 after purchasing an additional 795 shares during the last quarter. Geode Capital Management LLC boosted its stake in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company's stock valued at $4,840,000 after buying an additional 1,138 shares in the last quarter. Rhumbline Advisers grew its position in XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company's stock valued at $230,000 after acquiring an additional 1,334 shares during the last quarter. State Street Corp raised its stake in XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company's stock worth $3,783,000 after acquiring an additional 1,754 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in shares of XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company's stock worth $1,484,000 after acquiring an additional 1,968 shares during the last quarter. 95.92% of the stock is currently owned by institutional investors and hedge funds.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.